coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Wallasey PCN, Wirral (LAD) · Health Inequalities Profile

    PCN U25656 · NHS Cheshire and Merseyside Integrated Care Board · 11 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    66,368

    Registered population

    60.2% aged 18–64

    20.5%

    Aged 65+

    ICB 19.0% · England 17.9%

    4.5%

    Ethnic minority (non-White)

    1.7% Asian · England 9.6%

    48.1%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~31,329

    Core20 residents (est.)

    Resident basis; registered basis ~32,419 · see page 3

    11,760

    Hypertension register

    +7.01% in 3 yrs · England +5.60%

    815

    SMI register

    20.4% of Wirral (LAD)'s

    1,871

    COPD register

    Reviews +6.73% in 3 yrs

    Forecast to 2030

    13,612

    Hypertension patients, 2030

    +1,852 on today

    80.1%

    QRISK ≥20% on statins, 2030

    +5.69pp over 3 yrs

    5.5%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    61.3%
    Asthma and COPD annual reviews trail England.

    Asthma reviews cover 61.3% of 5,360 patients (England 65.7%; 2,073 unreviewed) and COPD 70.0% (England 76.4%), which may reflect unverified recall barriers.

    91.3%
    Primary CVD control leads while diabetes statins lag.

    Hypertension BP monitoring reaches 91.3% (target treatment 70.2%) and QRISK ≥ 20% lipid therapy 67.0%, though diabetes-with-CVD statins are 83.2% (-0.01% 3-year change).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older patients comprise 20.5% of registrations alongside 26 catchment care homes

    Wallasey PCN registers 66,368 patients, with 26 catchment care homes (744 beds; resident registrations unconfirmed). Patients aged 65 and over make up 20.5% of the list (13,621 patients), close to Wirral (LAD) (20.7%) but above NHS Cheshire and Merseyside Integrated Care Board (19.0%) and England (17.9%). Working-age adults represent 60.2% (39,961) and children aged 0-17 comprise 19.3% (12,786). Projected list growth to 2030 is 0.8% (Wirral (LAD) 1.2%, ICB 2.3%, England 2.3%; unverified methodology). Census data shows 95.5% White residents (Wirral (LAD) 95.2%, England 81.1%), leaving a 4.5% ethnic minority share; Census residents differ from registered patients.

    Age profile

    0–1719.3%
    18–6460.2%
    65+20.5%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White95.5%
    Asian1.7%
    Mixed1.7%
    Other0.6%
    Black0.4%

    Older people · falls rows are Wirral (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Wirral LA)1,5172,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)86.1%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)57.1%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Wirral LA)7531,0219552024/25
    Falls deaths, all ages, per 100,000 (Wirral LA)25.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Wallasey PCN has 48.1% Core20 deprivation with a 96.7 pp spread across practices

    In Wallasey PCN, 48.1% of registered patients live in Core20 areas, above Wirral (34.8%), the ICB (31.9%) and England (21.0%). Average IMD decile is 3.5 (England 5.5). Weighted practice share is 48.8%. Across captured practices, the range is 96.7 pp. Grove Rd Surgery records 3.4%, whereas Egremont Med Ctr and Leasowe Medical Practice each reach 100.0%. Somerville Med Ctr (7,092) and Central Park Medical Centre (6,437) hold the largest estimated Core20 volumes. Resident Core20 totals 31,329. Delivery should split intensive outreach at high-concentration practices from proactive volume recall.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Egremont Med Ctr100.0% · 4,716 patients
    Leasowe Medical100.0% · 2,803 patients
    Liscard78.4% · 3,571 patients
    Somerville Med75.4% · 7,092 patients
    Central Park72.7% · 6,437 patients
    Blackheath Med56.0% · 2,385 patients
    Manor Health Ctr47.3% · 2,654 patients
    St Georges19.8% · 1,791 patients
    St Hilary6.7% · 392 patients
    Village6.5% · 413 patients
    Grove Rd3.4% · 165 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    815

    SMI register

    1.22% recorded prevalence

    484

    Learning disability register

    0.72% recorded prevalence

    26

    Care homes, 744 beds

    In the PCN catchment

    10.9%

    Provide unpaid care

    Wirral (LAD), Census 2021

    Severe mental illness prevalence is 1.2% (815 patients; Wirral (LAD) 1.2%, ICB 1.1%, England 1.0%), representing 20.4% of Wirral's register. Learning disability prevalence is 0.7% (484 patients; Wirral (LAD) 0.8%, ICB 0.6%, England 0.6%). Crude recorded register prevalence does not establish unmet need or under-detection.

    Severe mental illness: physical health checks

    SMI prevalence is 1.2% (England 1.0%). Recorded checks exceed England: blood pressure reaches 87.1% (England 83.4%), BMI 83.8% (England 82.1%), and smoking cessation offer 97.5% (England 94.2%), though smoking support fell 0.7 pp (England +0.1 pp).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    11,760

    Hypertension register

    +7.01%

    Register growth, 3 yrs

    Wirral (LAD) +6.35% · England +5.60%

    +4.56pp

    BP control, under 80

    ≤140/90 · +4.05pp aged 80+

    +1,852

    More patients by 2030

    Forecast 13,612 (20.12%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 17.6% (11,760 patients), exceeding England (15.2%) and NHS Cheshire and Merseyside Integrated Care Board (16.8%), while below Wirral (LAD) (18.0%). Blood pressure monitoring reaches 91.3% (England 90.0%; Wirral (LAD) 89.2%; ICB 88.3%), and treatment to target reaches 70.2% (Wirral (LAD) 67.9%; England 70.3%). However, secondary cardiovascular prevention lags: statin treatment in diabetes with CVD is 83.2%, trailing England (84.4%) and Wirral (LAD) (85.1%), with a 3-year change of -0.01% (England +1.0%). Statin treatment in diabetes with established CVD trails national and borough levels, indicating that the PCN should prioritise secondary-prevention recall for high-risk diabetic patients.

    Lipids and statins

    Patients with QRISK ≥ 20% receiving lipid-lowering therapy reach 67.0%, above England (63.6%) and Wirral (LAD) (65.8%), alongside 74.0% in CKD (England 70.3%). Higher treatment rates than England across primary prevention groups indicate the PCN should sustain systematic cardiovascular risk assessment and lipid initiation.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026145,777£2.40£1.71£1.86£349,865
    Cardiovascular (all), 2025192,077£4.91£4.37£3.33£943,098

    In 2026, lipid-modifying prescribing cost £2.40 per item across 145,777 items (spend £349,865), exceeding England (£1.86) and Wirral (LAD) (£2.00). This unit cost is £78,720 more than at England's unit cost across 145,777 items. Higher unit costs than England could reflect formulary choices, which a practice-level prescribing review would test.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +3.06%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +2.09%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 8.5% (5,360 patients; England 6.6%) and COPD is 2.8% (1,871 patients; England 1.9%), alongside 2,867 asthma items prescribed per 1,000 aged 5-19 (England 1,488 rate). Yet annual reviews trail England for asthma at 61.3% (England 65.7%; Wirral (LAD) 63.2%; a modelled scale indicator of about 2,100 unreviewed patients) and COPD at 70.0% (England 76.4%). Lower review coverage alongside high prescribing could reflect recall barriers, which local practice audits would test.

    Cancer register and children's immunisation

    Cancer register prevalence is 4.4% (2,964 patients; England 3.8%). In childhood immunisations, age-5 MMR dose 1 reaches 97.9% (England 91.7%), but dose 2 drops 4.8 pp to 93.1%, sitting 1.9 pp below the 95.0% target. The 4-in-1 pre-school booster is also 93.1%, trailing the 95.0% target by 1.9 pp despite exceeding England (80.9%). Denominators are small (145 children).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months90.9%

    England 91.0%

    6-in-1 complete primary course at 24 months92.9%

    England 92.2%

    MMR dose 1 at 24 months90.1%

    England 88.3%

    MMR dose 2 at age 593.1%

    England 82.8%

    4-in-1 pre-school booster at age 593.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), 19.5 pp below the 75.0% national ambition for 2028; staging completeness was 72.8% (13,490 of 18,522). Sizing this ICB gap indicates 2,635.5 (about 2,640) extra early-stage diagnoses were required in 2022, while early-stage share rose 2.6 pp from 2013 to 2022. At PCN level, cervical screening coverage is 69.4% (Wirral (LAD) 71.5%), with a 3-year change of -1.1% (Wirral (LAD) +1.2%). Screening rates below the borough may delay early cancer detection, making practice recall audits a priority.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    For secondary cancer pathway standards, Wirral University Teaching Hospital NHS Foundation Trust achieved 77.647% against the 85.0% 62-day referral-to-treatment standard (7.4 pp below the standard) and 74.7058% on the 28-day faster diagnosis standard (0.3 pp below the 75.0% target), alongside 92.5266% on the 31-day combined standard (target 96.0%). Across NHS Cheshire and Merseyside Integrated Care Board, 62-day performance was 76.232% (8.8 pp below standard), 28-day faster diagnosis reached 77.2451% (2.2 pp above standard), and 31-day treatment was 95.7087% (0.3 pp below standard). These acute trust metrics describe system delays rather than PCN referral quality.

    Pathways within standard (%)WirralLiverpoolMersey and West LancashireCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)74.7175.4772.3977.2579.32
    31-day treatment (96%)92.5390.5195.4695.7192.50
    62-day referral to treatment (85%)77.6573.2677.9676.2371.16
    Diagnostic waits over 6 weeks (%)WirralLiverpoolMersey and West LancashireEngland
    MRI1.546.4214.0421.40
    CT1.550.7113.089.92
    Echocardiography5.0712.5534.8828.48
    Colonoscopy32.8133.1418.0430.83
    Gastroscopy17.7344.9918.1729.02
    All 15 DM01 tests5.0211.5021.1723.14
    Community services activityWirral residentsCheshire and Merseyside ICB
    Care contacts58,870541,280
    Referrals13,31597,150
    Patients with a contact17,205146,240

    Community services (residents of Wirral), Jun 2026 (provisional). In community health services activity, adults aged 65 and over accounted for 66.1% of all community contacts among Wirral borough residents (38,930 of 58,870 contacts, provisional June 2026 data). These figures capture borough-wide resident contacts rather than PCN-level delivery, reflecting high routine community care intensity for older adults across the local authority.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Grove Rd Surgery1173.485.4%63.4%95.2%
    Blackheath Med Ctr11056.090.1%67.1%93.3%
    Liscard9578.464.3%56.8%91.8%
    Somerville Med Ctr12575.445.4%84.0%90.4%
    Manor Health Ctr11747.388.7%90.1%88.8%
    Leasowe Medical102100.075.9%63.7%87.4%
    St Hilary1196.766.2%64.8%85.5%
    Village956.577.5%68.9%84.1%
    Central Park11472.752.8%71.7%79.6%
    Egremont Med Ctr106100.065.2%76.5%76.6%
    St Georges12319.841.6%68.0%66.7%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWirral (LAD)AssetPCNWirral (LAD)
    Care homes (catchment)26 (744 beds)n/aSchools (catchment)42n/a
    Children's centres416Places of worship38171
    Libraries318Primary schools (LA maintained)1552
    Primary academies336Special schoolsn/a3

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured respiratory annual review recall

    Asthma review coverage is 61.3% of 5,360 patients (England 65.7%; Wirral (LAD) 63.2%), leaving a scale indicator of 2,073 (about 2,100) unreviewed patients; COPD reviews are 70.0% (England 76.4%). For discussion: run structured asthma and COPD review and inhaler recall clinics, starting at high-volume and high-share Core20 practices. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Two-track Core20 and diabetes recall

    Core20 share is 48.1% (England 21.0%; Wirral (LAD) 34.8%; 31,329 estimated residents; 96.7 pp spread). Diabetes statins with CVD (83.2% vs England 84.4%) and non-frail HbA1c <= 58 mmol/mol (57.1% vs Wirral (LAD) 58.1%) trail. Moderate effort to run.

    Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.

    Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.

    Option 3

    Dementia and learning disability register validation

    Dementia is 0.8% (524 patients; Wirral (LAD) 1.0%; gap -5 to +122; 3-year growth +0.9% vs England +6.0%); learning disability is 0.7% (484 patients; gap -94 to +38; growth +0.5% vs England +5.4%). Low cost, quick to run.

    Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.

    Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Care home primary care alignment (p2)Count of care home beds in PCN catchmentFit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026PCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Sustained SMI physical health monitoring (p4)Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Secondary prevention diabetic statin audit (p5)Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs)NHS Long Term Plan (diabetes) and National Diabetes AuditPCN
    Second dose MMR recall audit (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Structured respiratory annual review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Two-track Core20 and diabetes recall (p12)Core20 cohort (IMD quintile 1) · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs)NHS Long Term Plan (diabetes) and National Diabetes AuditPCN & Practice
    Option 3 · Dementia and learning disability register validation (p12)Dementia register · Dementia: QOF prevalence · Learning disability register66.7% diagnosis ambition · 95% care plan 2027 · 75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15